Why is Cohance Lifesciences Ltd falling/rising?

Recent Price Movement and Market Performance

The stock has been under significant pressure over the past week, registering a decline of 10.63%, which starkly contrasts with the Sensex’s modest 1.69% fall during the same period. Over the last month, the stock’s depreciation deepened to 16.20%, far exceeding the benchmark’s 1.92% drop. Year-to-date, Cohance Lifesciences has lost nearly 15%, while the Sensex has declined by less than 2%. This persistent underperformance is further underscored by the stock hitting a new 52-week low of ₹443.25 on 13-Jan, signalling sustained selling pressure.

Adding to the bearish sentiment, the stock has been falling consecutively for four days, losing over 10.8% in that span. Intraday trading on 13-Jan saw the share price dip as low as ₹443.25, a 2.96% drop from the previous close, with heavier volumes concentrated near these lower price levels. This pattern suggests that sellers dominated the session, pushing prices downwards. Furthermore, the stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a strong bearish technical setup.

Investor Participation and Liquidity

Investor engagement appears to be waning, as evidenced by a 9.87% decline in delivery volume on 12-Jan compared to the five-day average. Although liquidity remains adequate for trades up to ₹1.04 crore based on recent average traded values, the falling participation hints at reduced confidence among investors, which often exacerbates downward price momentum.

Fundamental Challenges Weighing on the Stock

Despite a commendable management efficiency reflected in a return on equity (ROE) of 21.07% and a low average debt-to-equity ratio of zero, the company’s financial performance has raised concerns. Operating profit growth has been sluggish, averaging a mere 4.15% annually over the past five years, which is insufficient to inspire investor confidence in the company’s growth trajectory.

The latest quarterly results for September 2025 further dampened sentiment. Operating cash flow for the year stood at ₹301.03 crore, the lowest recorded, signalling potential liquidity constraints. Profit before tax excluding other income fell sharply by 42.4% compared to the previous four-quarter average, settling at ₹68.17 crore. Net profit after tax also declined by 27.4% to ₹74.08 crore in the same period. These negative earnings trends have contributed to the stock’s steep decline over the past year.

Valuation Concerns and Promoter Share Pledging

The stock’s valuation appears stretched, trading at a price-to-book value of 4.5, which is high relative to its peers and historical averages. This premium valuation is difficult to justify given the company’s modest ROE of 9.1% and deteriorating profitability. Over the last year, while profits have increased by 9.5%, the stock price has plummeted by 57.25%, reflecting a disconnect between market expectations and financial realities.

Adding to the bearish outlook is the fact that 100% of promoter shares are pledged. In volatile or falling markets, such high promoter pledging often exerts additional downward pressure on share prices, as any margin calls or forced selling can exacerbate declines.

Overall, Cohance Lifesciences has underperformed not only the Sensex but also the broader BSE500 index over the last one year, three years, and three months, highlighting its below-par performance both in the short and long term.

Conclusion: Why the Stock is Falling

The decline in Cohance Lifesciences Ltd’s share price on 13-Jan is the result of a combination of weak financial results, poor long-term growth prospects, expensive valuation metrics, and market concerns over promoter share pledging. The stock’s consistent underperformance relative to benchmarks and falling investor participation further compound the negative sentiment. While the company demonstrates strong management efficiency and a clean balance sheet, these positives have been overshadowed by disappointing earnings and cash flow metrics, leading to sustained selling pressure and a new 52-week low.

Investors should carefully weigh these factors before considering exposure to Cohance Lifesciences, especially given the availability of potentially more attractive alternatives within the pharmaceuticals and biotechnology sectors.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →